var data={"title":"Progesterone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Progesterone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6847?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=progesterone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Progesterone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709349\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular disorders (capsule):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not use progestins plus estrogens for the prevention of cardiovascular disease.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of myocardial infarction (MI), stroke, pulmonary embolism (PE), and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens 0.625 mg combined with medroxyprogesterone 2.5 mg relative to placebo.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Probable dementia (capsule):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not use progestins plus estrogens for the prevention of dementia.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The Women's Health Initiative Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years and older during 4 years of treatment with daily conjugated estrogens 0.625 mg combined with medroxyprogesterone 2.5 mg, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Breast cancer (capsule):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">In the absence of comparable data, assume these risks to be similar for other doses of conjugated estrogens and medroxyprogesterone and other combinations and dosage forms of estrogens and progestins.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks versus benefits (capsule):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prescribe progestins with estrogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213986\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Crinone;</li>\n      <li>EC-RX Progesterone;</li>\n      <li>Endometrin;</li>\n      <li>First-Progesterone VGS 100;</li>\n      <li>First-Progesterone VGS 200;</li>\n      <li>First-Progesterone VGS 25 [DSC];</li>\n      <li>First-Progesterone VGS 400 [DSC];</li>\n      <li>First-Progesterone VGS 50 [DSC];</li>\n      <li>Prometrium</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213987\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Progesterone Injection;</li>\n      <li>Crinone;</li>\n      <li>Endometrin;</li>\n      <li>Gesterol in Oil;</li>\n      <li>PMS-Progesterone Injection;</li>\n      <li>Prometrium;</li>\n      <li>TEVA-Progesterone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214026\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Progestin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213991\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Females:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amenorrhea:</b> IM: 5 to 10 mg/day for 6 to 8 consecutive days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amenorrhea, secondary:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intravaginal gel:</i> 45 mg (4% gel) every other day for up to a total of 6 doses; if response is inadequate, may increase to 90 mg (8% gel) at same schedule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> 400 mg once daily at bedtime for 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ART in patients who require progesterone supplementation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intravaginal gel:</i> 90 mg (8% gel) once daily. If pregnancy occurs, may continue treatment for up to 10 to 12 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intravaginal insert:</i> 100 mg 2 to 3 times daily starting the day after oocyte retrieval and continuing for up to 10 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ART in patients with partial or complete ovarian failure:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intravaginal gel:</i> 90 mg (8% gel) twice daily. If pregnancy occurs, continue treatment for up to 10 to 12 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial hyperplasia, prevention</b> (in postmenopausal women with a uterus who are receiving conjugated estrogen daily): Oral: 200 mg once daily at bedtime for 12 days sequentially per 28-day cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uterine bleeding (functional):</b> IM: 5 to 10 mg/day for 6 doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of spontaneous preterm delivery (singleton pregnancy and prior preterm birth or short cervix) (off-label use):</b> Intravaginal gel: 90 mg (8% gel) once daily (Hassan 2011; O'Brien 2009). Treatment initiation is recommended before or at gestational week 24 (ACOG 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213992\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22626101\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Injection, oral: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Intravaginal gel, insert: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22626102\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in hepatic impairment or disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213962\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prometrium: 100 mg [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), peanut oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prometrium: 100 mg [DSC] [contains peanut oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prometrium: 200 mg [contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow), peanut oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prometrium: 200 mg [DSC] [contains peanut oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EC-RX Progesterone: 10% (30 g, 60 g); 20% (30 g, 60 g) [contains cetearyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Vaginal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Crinone: 4% (1.125 g); 8% (1.125 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Insert, Vaginal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endometrin: 100 mg (21 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oil, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suppository, Vaginal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Progesterone VGS 25: 25 mg (30 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Progesterone VGS 50: 50 mg (30 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Progesterone VGS 100: 100 mg (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Progesterone VGS 200: 200 mg (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Progesterone VGS 400: 400 mg (30 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213946\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26975053\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Progesterone cream 10% and vaginal suppositories are compounding kits. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213966\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer deep IM only. May cause injection-site irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravaginal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vaginal gel: A small amount of gel will remain in the applicator following insertion. Administer into the vagina directly from sealed applicator. Remove applicator from wrapper; holding applicator on each side, push plunger into applicator until it snaps into place; twist off cap counterclockwise; gently insert into vagina and push plunger.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vaginal insert: Insert tablet in vagina using disposable applicator provided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: For patients who experience difficulty swallowing the capsules, taking with a full glass of water in the standing position may be beneficial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133434\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. For IM preparation, NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator). Double gloving and a protective gown are required during IM administration. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213965\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Prevention of endometrial hyperplasia in nonhysterectomized, postmenopausal women who are receiving conjugated estrogens; treatment of secondary amenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Treatment of amenorrhea or abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravaginal gel: Part of assisted reproductive technology (ART) for infertile women with progesterone deficiency; treatment of secondary amenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaginal insert: To support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of ART for infertile women</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25471493\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Reduce the risk of recurrent spontaneous preterm birth</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213953\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intramuscular injection</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cerebral thrombosis, edema, pulmonary embolism, retinal thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Cerebral edema, depression, drowsiness, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, hirsutism, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea, change in menstrual flow, galactorrhea, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Breakthrough bleeding, breast tenderness, cervical erosion, change in cervical secretions, spotting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site, irritation at injection site, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Optic neuritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Allergic dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral </b>(percentages reported when used in combination with or cycled with conjugated estrogens):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (16% to 31%), dizziness (15% to 24%), depression (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Breast tenderness (27%), mastalgia (6% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (10% to 20%), bloating (8% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urination disorder (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (20%), musculoskeletal pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (8%), fatigue (8%), irritability (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;8%), vomiting (&le;8%), diarrhea (7% to 8%), cholecystectomy (&lt;5%), constipation (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal discharge (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Malignant neoplasm of breast (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Abnormal gait, acute pancreatitis, aggressive behavior, alopecia, anaphylaxis, arthralgia, asthma, blurred vision, choking sensation, cholestasis, cholestatic hepatitis, circulatory shock, confusion, depersonalization, diplopia, disorientation, dysarthria, dysphagia, dyspnea, endometrial carcinoma, facial edema, feeling abnormal, increased liver enzymes, hepatic failure, hepatic necrosis, hepatitis, hyperglycemia, hypermenorrhea, hypersensitivity reaction, hypertension, hypotension, impaired consciousness, intoxicated feeling, jaundice, loss of consciousness, menstrual disease, muscle cramps, ovarian cyst, paresthesia, pharyngeal edema, pruritus, sedation, seizure, slurred speech, stupor, suicidal ideation, syncope, tachycardia, tinnitus, tongue edema, transient ischemic attacks, urticaria, uterine hemorrhage, vertigo, visual disturbance, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Vaginal gel</b> (percentages reported with ART):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (27%), headache (13% to 17%), nervousness (16%), depression (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased libido (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (27%), nausea (7% to 22%), abdominal cramps (15%), abdominal pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Breast hypertrophy (40%), perineal pain (17%), mastalgia (13%), nocturia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (8%), dizziness (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Genital pruritus (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (8%), bloating (7%), vomiting (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal discharge (7%), dyspareunia (6%), genital candidiasis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Vaginal insert</b> (percentages reported with ART):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (post-oocyte retrieval pain: 25% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 4%), fatigue (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Ovarian hyperstimulation syndrome (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (7% to 8%), abdominal distention (4%), constipation (2% to 3%), vomiting (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Uterine spasm (3% to 4%), vaginal hemorrhage (3%), urinary tract infection (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Genital pruritus, local discomfort, peripheral edema, urticaria, vulvovaginal burning, vulvovaginal irritation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213969\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Hypersensitivity to progesterone or any component of the formulation, including peanuts/peanut oil; undiagnosed abnormal genital bleeding; breast cancer (known, suspected, or history of); active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or history of arterial thromboembolic disease (eg, stroke, MI); hepatic impairment or disease; pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Hypersensitivity to progesterone or any component of the formulation, including sesame oil/seeds; active or history of thrombophlebitis, thromboembolic disorders, or cerebral apoplexy; undiagnosed vaginal bleeding; hepatic impairment or disease; known or suspected malignancy of the breast or genital organs; missed abortion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravaginal gel: Hypersensitivity to progesterone or any component of the formulation, including palm oil; undiagnosed vaginal bleeding; hepatic impairment or disease; known or suspected malignancy of the breast or genital organs; missed abortion; active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaginal insert: Hypersensitivity to progesterone or any component of the formulation; undiagnosed vaginal bleeding; known missed abortion or ectopic pregnancy; hepatic disease; known or suspected malignancy of the breast or genital organs; active or history of arterial or venous thromboembolism or severe thrombophlebitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Canadian labeling: Additional contraindications (not in the US labeling): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Capsules: Hypersensitivity to soya; endometrial hyperplasia; classical migraine; partial or complete loss of vision due to ophthalmic vascular disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Intravaginal gel: Acute porphyria, cerebral apoplexy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Vaginal insert/tablet: Porphyria; undiagnosed vaginal bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Documentation of allergenic cross-reactivity for progestins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213950\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer: <b>[US Boxed Warning]: In the Women's Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in women &ge;65 years with daily conjugated estrogens combined with medroxyprogesterone.</b> This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson 2012). An increase in abnormal mammogram findings has also been reported with estrogen in combination with progestin therapy. Use is contraindicated in patients with known or suspected breast cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Progestin plus estrogens should not be used for the prevention of dementia. In the Women's Health Initiative Memory Study (WHIMS), an increased risk of developing probable dementia was observed in women &ge;65 years with daily conjugated estrogens combined with medroxyprogesterone.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endometrial cancer: Progesterone is used to reduce the risk of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogens. The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal persistent or recurring vaginal bleeding. Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: May cause fluid retention; use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, cardiac impairment, epilepsy, migraine, and diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian cancer: Progesterone plus estrogen therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Retinal vascular thrombosis: Discontinue pending examination in cases of sudden partial or complete vision loss, sudden onset of proptosis, diplopia, or migraine; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: <b>[US Boxed Warning]: Progestin plus estrogen should not be used for the prevention of cardiovascular disease. In the WHI studies, an increased risk of DVT, PE, stroke, and myocardial infarction was observed in women &ge;65 years with daily conjugated estrogens combined with medroxyprogesterone. </b>Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with a history of depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes; decreased glucose tolerance may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use is contraindicated in hepatic impairment or disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; progestins may cause fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not for use prior to menarche.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Whenever possible, progestins in combination with estrogens should be discontinued at least 4 to 6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Palm oil: Some products may contain palm oil.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peanut oil: Some products may contain peanut oil.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sesame oil: Some products may contain sesame oil.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Risks vs benefits: Oral: <b>[US Boxed Warning]: Progestin with estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</b> Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from WHI studies, which evaluated oral conjugated estrogens with medroxyprogesterone relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied. <b>Outcomes reported from clinical trials using conjugated estrogens with medroxyprogesterone should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F214021\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2C19 (major), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213955\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9817&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Vaginal): May diminish the therapeutic effect of Progesterone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Progestins may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Progestins may enhance the thrombogenic effect of Pomalidomide.  Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Progestins may diminish the therapeutic effect of Ulipristal. Ulipristal may diminish the therapeutic effect of Progestins.  Management: Ulipristal for uterine fibroids (Canadian indication): avoid progestins within 12 days of stopping ulipristal; as emergency contraceptive (U.S. indication): avoid progestins within 5 days of stopping ulipristal.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213981\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food increases oral bioavailability. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213958\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (oral) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213972\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">The oral capsules are contraindicated for use during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events have not been observed following oral administration in animal reproduction studies. Adverse events following maternal use in pregnancy (eg, hypospadias, congenital heart disease, cleft lip/palate) have been noted in postmarketing data; however, a causal relationship has not been clearly established. Use of vaginal progesterone may be considered to decrease the risk of recurrent spontaneous preterm birth in women with a singleton pregnancy and prior spontaneous preterm singleton birth (therapy may begin at 16 to 24 weeks, regardless of cervical length). It may also be used to prevent spontaneous preterm birth in women with a singleton pregnancy who have a cervix &lt;20 mm before or at 24 weeks' gestation. Use is not recommended as an intervention for women with multiple gestations (ACOG 2012). The vaginal gel and insert are indicated for use in ART.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20688475\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Progesterone is excreted in breast milk. The manufacturer recommends that caution be used if progesterone is administered to a nursing woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213960\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Signs and symptoms of thromboembolic disorders, vision changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213949\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Natural steroid hormone that induces secretory changes in the endometrium, promotes mammary gland development, relaxes uterine smooth muscle, blocks follicular maturation and ovulation, and maintains pregnancy. When used as part of an ART program in the luteal phase, progesterone supports embryo implantation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213968\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Vaginal gel: Prolonged</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Absorption half-life: Vaginal gel: ~25 to 50 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~96% to 99%, primarily to albumin (50% to 54%) and cortisol-binding protein (43% to 48%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to pregnanediols and pregnanolones, which are then conjugated to glucuronide and sulfate metabolites; metabolites excreted in the bile may be deconjugated and further metabolized in the intestine via reduction, dehydroxylation, and epimerization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Vaginal gel: 5 to 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Oral: Within 3 hours; IM: ~8 hours; Intravaginal gel: 3.55 &plusmn; 2.48 to 7 &plusmn; 2.88 hours; Vaginal insert: 17.3 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (50% to 60% as metabolites); bile, feces (~10%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213971\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Progesterone Micronized Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $210.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $400.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Prometrium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $694.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $1,319.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Progesterone Micronized Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (60 g): $398.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Crinone Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (1.125 g): $20.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8% (1.125 g): $34.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>INST</b> (Endometrin Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (21): $282.67</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Progesterone Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (10 mL): $35.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (First-Progesterone VGS 100 Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $192.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (First-Progesterone VGS 200 Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $202.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213973\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Crinone (AR, AU, BE, BH, BR, CH, CL, CN, CO, CU, CY, DE, DK, ES, FI, GB, GR, HK, HR, ID, IE, IL, IT, KR, KW, LB, LK, LU, MT, MY, NO, NZ, PH, RU, SE, SG, SK, TR, TW, VE, VN);</li>\n      <li>Cyclogest (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MY, OM, PK, QA, SA, SG, SY, VN, YE, ZA);</li>\n      <li>Cygest (ID);</li>\n      <li>Darstin (ES);</li>\n      <li>Endometrin (HK, IL, VN);</li>\n      <li>Endometrin Vaginal (SG);</li>\n      <li>Estima Ge (FR);</li>\n      <li>Farlutal (AE, EG, SA);</li>\n      <li>Farlutal Depot (BH, QA);</li>\n      <li>Gepretix (LV);</li>\n      <li>Gepromi (MX);</li>\n      <li>Geslutin (CO, MX, VE);</li>\n      <li>Geslutin PNM (CR, DO, EC, GT, HN, NI, PA, PE, SV);</li>\n      <li>Gester (AR);</li>\n      <li>Gestron (PH);</li>\n      <li>Glanducorpin (HU);</li>\n      <li>Gynprogest (PY);</li>\n      <li>Jarit (CO);</li>\n      <li>Krynon (UA);</li>\n      <li>Lubion (GB);</li>\n      <li>Luteina (PL);</li>\n      <li>Luteum (JP);</li>\n      <li>Lutigest (GB);</li>\n      <li>Lutinus (IE, JP);</li>\n      <li>Mafel (AR, PY);</li>\n      <li>Microgest (BD);</li>\n      <li>Naturogest (IN);</li>\n      <li>Onecrinone (JP);</li>\n      <li>ProFeme 10 (AU);</li>\n      <li>ProFeme 3.2 (AU);</li>\n      <li>Progeffik (TW);</li>\n      <li>Progendo (CL, EC, VN);</li>\n      <li>Progering (PE);</li>\n      <li>Progestan (NL);</li>\n      <li>Progestogel (LU);</li>\n      <li>Prohynorm (UA);</li>\n      <li>Prolutex (ES);</li>\n      <li>Prometrium (BB, BM);</li>\n      <li>Prostium (LK);</li>\n      <li>Susten (LK);</li>\n      <li>Utrogestan (AR, AT, BE, BG, BR, CH, CO, CZ, ES, FR, GB, HR, HU, ID, JO, JP, KR, LB, LU, LV, MT, MX, MY, NZ, PE, PH, PT, RO, SG, SK, TR, UY, VE, VN);</li>\n      <li>Utrozhestan (UA);</li>\n      <li>Vrinone (AE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GL, Chlebowski RT, Aragaki AK, et al, &quot;Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,&quot; <i>Lancet Oncol,</i> 2012, 13(5):476-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/22401913/pubmed\" target=\"_blank\" id=\"22401913\">22401913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GL, Limacher M, Assaf AR, et al, &quot;Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.&quot; <i>JAMA</i>, 2004, 291(14):1701-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/15082697/pubmed\" target=\"_blank\" id=\"15082697\">15082697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cetingoz E, Cam C, Sakalh M, et al. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. <i>Arch Gynecol Obstet.</i> 2011283(3):423-429.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/20091317/pubmed\" target=\"_blank\" id=\"20091317\">20091317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chlebowski RT, Kuller LH, Prentice RL, et al, &quot;Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,&quot; <i>N Engl J Med</i>, 2009, 360(6):573-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/19196674/pubmed\" target=\"_blank\" id=\"19196674\">19196674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22996126\"></a>Committee on Practice Bulletins&mdash;Obstetrics, The American College of Obstetricians and Gynecologists (ACOG). Practice bulletin no. 130: prediction and prevention of preterm birth. <i>Obstet Gynecol.</i> 2012;120(4):964-973.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/22996126/pubmed\" target=\"_blank\" id=\"22996126\">22996126</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26605928\"></a>Coomarasamy A, Williams H, Truchanowicz E, et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. <i>N Engl J Med</i>. 2015;373(22):2141-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/26605928/pubmed\" target=\"_blank\" id=\"26605928\">26605928</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crinone (progesterone) [prescribing information]. Parsippany, NJ: Actavis Pharma; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crinone (progesterone) [product monograph]. Mississauga, Ontario, Canada: EMD Inc, Canada; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doody KJ1, Schnell VL, Foulk RA,et al. Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. <i>Fertil Steril.</i> 2009;91(4):1012-1017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/18371963/pubmed\" target=\"_blank\" id=\"18371963\">18371963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Endometrin (progesterone) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Endometrin (progesterone) [product monograph]. North York, Ontario, Canada: Ferring Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fonseca EB, Celik E, Parra M, Singh M, and Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. <i>N Engl J Med.</i> 2007;375(5):462-469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/17671254/pubmed\" target=\"_blank\" id=\"17671254\">17671254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. <i>Ultrasound Obstet Gynecol.</i> 2011;38(1):18-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/21472815/pubmed\" target=\"_blank\" id=\"21472815\">21472815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsia J, Langer RD, Manson JE, et al, &quot;Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,&quot; <i>Arch Intern Med</i>, 2006, 166(3):357-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/16476878/pubmed\" target=\"_blank\" id=\"16476878\">16476878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meis PJ, Klebanoff M, Thom E, et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate [published correction appears in <i>N Engl J Med</i>. 2003;349(13):1299]. <i>N Engl J Med.</i> 2003;348(24):2379-2385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/12802023/pubmed\" target=\"_blank\" id=\"12802023\">12802023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo; <i>JAMA</i>, 2009, 302(3):298-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/19602689/pubmed\" target=\"_blank\" id=\"19602689\">19602689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ng EH, Chan CC, Tang OS, et al, &ldquo;A Randomized Comparison of Side Effects and Patient Convenience Between Cyclogest&reg; Suppositories and Endometrin&reg; Tablets Used for Luteal Phase Support in IVF Treatment,&rdquo; <i>Eur J Obstet Gynecol Reprod Biol</i>, 2007, 131(2):182-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/16920249/pubmed\" target=\"_blank\" id=\"16920249\">16920249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    North American Menopause Society [NAMS], &quot;The 2012 Hormone Therapy Position Statement of The North American Menopause Society,&quot; <i>Menopause</i>, 2012, 19(3):257-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/22367731/pubmed\" target=\"_blank\" id=\"22367731\">22367731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Brien JM1, Defranco EA, Adair CD, et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. <i>Ultrasound Obstet Gynecol.</i> 2009;34(6):653-659.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/19918965/pubmed\" target=\"_blank\" id=\"19918965\">19918965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Progesterone injection [prescribing information]. Parsippany, NJ: Actavis Pharma; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prometrium (progesterone) [prescribing information]. Tampa, FL: Virtus Pharmaceuticals; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prometrium (progesterone) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. <i>Am J Obstet Gynecol.</i> 2012;206(2):124.e1-124.e19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/22284156/pubmed\" target=\"_blank\" id=\"22284156\">22284156</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;<i>JAMA</i>, 2002, 288(3):321-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/12117397/pubmed\" target=\"_blank\" id=\"12117397\">12117397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2003, 289(20):2651-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/progesterone-drug-information/abstract-text/12771112/pubmed\" target=\"_blank\" id=\"12771112\">12771112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in the healthcare settings 2014. <a href=\"http://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf</a>. Updated September 2014. Accessed September 15, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9817 Version 210.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709349\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F213986\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F213987\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F214026\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F213991\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F213992\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22626101\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22626102\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F213962\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F213946\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F26975053\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F213966\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133434\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F213965\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25471493\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F213953\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F213969\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F213950\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F214021\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F213955\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F213981\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F213958\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F213972\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20688475\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F213960\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F213949\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F213968\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F213971\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F213973\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9817|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=progesterone-patient-drug-information\" class=\"drug drug_patient\">Progesterone: Patient drug information</a></li></ul></div></div>","javascript":null}